

02 Apr 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 31 March 2023, including: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[The 10 US Biosimilar Launches That Could Drive Big Savings By 2027](#)" - Scrip, 24 Mar, 2023.)

(Also see "[Novartis's Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting](#)" - Scrip, 27 Mar, 2023.)

(Also see "[Novartis's 'Poster Child' Zolgensma Shows What Gene Therapy Can Do – And Its Limitations](#)" - Scrip, 24 Mar, 2023.)

(Also see "[*Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads*](#)" - Scrip, 27 Mar, 2023.)

(Also see "[*Scrip Asks...What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion*](#)" - Scrip, 29 Mar, 2023.)

[*Click here to explore this interactive content online*](#) ✎